中国真菌学杂志2024，Vol.19Issue(1)：8-14,7.
传统两性霉素B和脂质体两性霉素B治疗血液病患者安全性的回顾性队列研究
Retrospective case-cohort study on safety of amphotericin B versus liposomal amphotericin B for hematologi-cal diseases
徐芳菲 1梁密 2黄伟1
作者信息
- 1. 华中科技大学同济医学院附属同济医院血液科,武汉 430030
- 2. 北京大学人民医院血液科,北京 100044
- 折叠
摘要
Abstract
Objective To compare the safety of conventional amphotericin B(C-AMB)versus liposomal amphotericin B(L-AMB)for hematological diseases by case-cohort study.Methods The clinical data of 595 cases of hematological diseases treated with C-AMB or L-AMB between 2016 and 2022 in the department of hematology of Tongji Hospital were collected and compared the difference of side effects between these two groups after matching patients'age and sex by propensity score matching analysis.Results There was no difference between C-AMB and L-AMB in the duration of treatment and in the in-cidence of drug withdrawal owing to either treatment success or treatment failure.And there was no difference between C-AMB and L-AMB in the incidence of drug withdrawal caused by hypokalemia,liver damage,and kidney damage.The differ-ence between patients treated with C-AMB and patients treated with L-AMB in the incidence of renal damage and the inci-dence of hypokalemia was not statistical significantly.The key factor affecting amphotericin B-induced nephrotoxicity and hy-pokalemia was the increasing maximum daily dose of amphotericin B.Conclusion C-AMB is still a safe and effective drug that is worthy of clinical use,especially for patients of hematological diseases with poor economic conditions,who need em-pirical therapy or pre-emptive therapy.关键词
传统两性霉素B/脂质体两性霉素B/药品安全/血液病Key words
conventional amphotericin B/liposomal amphotericin B/drug safety/hematological diseases分类
医药卫生引用本文复制引用
徐芳菲,梁密,黄伟..传统两性霉素B和脂质体两性霉素B治疗血液病患者安全性的回顾性队列研究[J].中国真菌学杂志,2024,19(1):8-14,7.
